Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Assets Average (2016 - 2025)

Seres Therapeutics' Assets Average history spans 11 years, with the latest figure at $143.6 million for Q3 2025.

  • For Q3 2025, Assets Average fell 42.6% year-over-year to $143.6 million; the TTM value through Sep 2025 reached $143.6 million, down 42.6%, while the annual FY2024 figure was $249.2 million, 29.54% down from the prior year.
  • Assets Average for Q3 2025 was $143.6 million at Seres Therapeutics, down from $154.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $387.0 million in Q3 2023 and bottomed at $143.6 million in Q3 2025.
  • The 5-year median for Assets Average is $324.3 million (2021), against an average of $290.3 million.
  • The largest annual shift saw Assets Average skyrocketed 172.29% in 2021 before it plummeted 56.56% in 2025.
  • A 5-year view of Assets Average shows it stood at $375.6 million in 2021, then decreased by 12.05% to $330.3 million in 2022, then grew by 9.94% to $363.1 million in 2023, then tumbled by 56.14% to $159.3 million in 2024, then dropped by 9.82% to $143.6 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Assets Average are $143.6 million (Q3 2025), $154.0 million (Q2 2025), and $152.0 million (Q1 2025).